Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Celltex Therapeutics has initiated talks with the US Food and Drug Administration (FDA) to conduct a study of adult, autologous mesenchymal stem cells (MSCs) for the treatment of Covid-19 symptoms.

The company assessed the safety and efficacy of MSCs in people with injuries, pain and conditions associated with autoimmune, vascular and other diseases such as pneumonia.

Celltex, in alliance with the Texas A&M University Institute for Regenerative Medicine, evaluated MSCs in Covid-19 patients. Data from this study showed that intravenous administration of clinical-grade human MSCs led to improved functional outcomes.

The editorial titled ‘Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (Covid-19) – Induced Pneumonia’ was published in the Aging and Disease journal.

During the study, intravenous MSCs were found to be safe and effective in treating novel coronavirus patients with pneumonia. The therapy is said to have yielded encouraging data even in elderly patients with severe pneumonia.